Last reviewed · How we verify
NCT05034783
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
EARLY_PHASE1 trial testing [68Ga]Ga-HBED-CC-exendin-4 in Insulinoma in 20 participants. Status unknown.
13 October 2022
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 20 |
| Start date | 1 October 2021 |
| Primary completion | 13 October 2022 |
| Estimated completion | 1 June 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- [68Ga]Ga-HBED-CC-exendin-4 — full drug profile →
- [68Ga]Ga-NOTA-exendin-4 — full drug profile →
Conditions studied
- Insulinoma — all drugs for Insulinoma →
Sponsor
Peking Union Medical College Hospital
Who can join
Adults 18 to 80, any sex, with Insulinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied \[68Ga\]Ga-NOTA-exendin-4. This pilot study was prospectively designed to evaluate the early dynamic distribution of \[68Ga\]Ga-HBED-CC-exendin-4, a novel radiopharmaceutical targeting GLP-1R, which was compared with \[68Ga\]Ga-NOTA-exendin-4 in the same group of insulinoma patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1.
Mena E, Lindenberg L, Herscovitch P, Sadowski SM, et al · · 2025 · cited 3× · PMID 40447542 · DOI 10.1053/j.semnuclmed.2025.05.001
Verify or expand the search:
- PubMed search for NCT05034783
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Insulinoma
Currently open trials in the same condition.
- NCT06725693 — Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease · recruiting
- NCT03583528 — DOTATOC PET/CT for Imaging NET Patients · active not recruiting
- NCT00001276 — Diagnosing and Treating Low Blood Sugar Levels · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05034783 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 14 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05034783.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing